Bicarbonate

Bicarbonate

SCHEMBL2497150

CCC.O=C(O)O.O=C(O)O

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 3/20 0.58
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA9 Q16790 1/20 0.56
HDAC1 Q13547 2/20 0.47
HDAC2 Q92769 2/20 0.47
HDAC3 O15379 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
TDP1 Q9NUW8 3/20 0.46
ALDH1A1 P00352 3/20 0.46
LCK P06239 1/20 0.46
FYN P06241 1/20 0.46
CES2 O00748 1/20 0.40
CES1 P23141 1/20 0.40
CHRM1 P11229 1/20 0.39
AKR1A1 P14550 1/20 0.39
CHRM3 P20309 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
ADRA1A P35348 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL591922 1.00 FFAR3 (0.58) FFAR3CA1CA2CA9HDAC1
Bicarbonate SCHEMBL1127897 1.00 FFAR3 (0.58) FFAR3CA1CA2CA9HDAC1
Bicarbonate SCHEMBL28893179 1.00 FFAR3 (0.58) FFAR3CA1CA2CA9HDAC1
Bicarbonate SCHEMBL28363045 1.00 FFAR3 (0.58) FFAR3CA1CA2CA9HDAC1
Bicarbonate SCHEMBL288699 1.00 FFAR3 (0.58) FFAR3CA1CA2CA9HDAC1
Bicarbonate SCHEMBL10955970 1.00 FFAR3 (0.58) FFAR3CA1CA2CA9HDAC1
Bicarbonate SCHEMBL7151962 1.00
Bicarbonate SCHEMBL20586919 0.95 FFAR3 (0.54) FFAR3CA1CA2CA9HDAC1
Bicarbonate SCHEMBL9435869 0.95 FFAR3 (0.54) FFAR3CA1CA2CA9HDAC1
Bicarbonate SCHEMBL17023327 0.95 FFAR3 (0.54) FFAR3CA1CA2CA9HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-5287113-A None JP disclosed
CN-115335045-B Modulators of mutation bestrophin for the treatment of BEST 1-related retinopathy 雷根斯堡大学 2025-03-18 CN disclosed
CN-115335045-A Mutant bestrophin 1 modulators for the treatment of BEST 1-related retinopathy 雷根斯堡大学 2022-11-11 CN disclosed
US-10758478-B2 Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same LABORATORY SKIN CARE, INC. (US) 2020-09-01 US disclosed
US-8030501-B2 Process for producing optically active 3-amino nitrogen-containing compounds KANEKA CORPORATION (JP) 2011-10-04 US disclosed
US-20090326246-A1 Method for Production of Optically Active 3-Amino-Nitrogenated Compound KANEKA CORPORATION (JP) 2009-12-31 US disclosed
EP-2050735-A1 METHOD FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-NITROGENATED COMPOUND Kaneka Corporation (JP) 2009-04-22 EP disclosed
US-7482415-B2 Process for producing fluoroionomer, method for purification and concentration of the ionomer, and method of film formation DAIKIN INDUSTRIES, LTD. (JP) 2009-01-27 US disclosed
EP-1283225-B1 PROCESS FOR PRODUCING FLUOROIONOMER, METHOD FOR PURIFICATION AND CONCENTRATION OF THE IONOMER, AND METHOD OF FILM FORMATION DAIKIN IND LTD (JP) 2006-05-03 EP disclosed
EP-1283225-A1 PROCESS FOR PRODUCING FLUOROIONOMER, METHOD FOR PURIFICATION AND CONCENTRATION OF THE IONOMER, AND METHOD OF FILM FORMATION Daikin Industries, Ltd. (JP) 2003-02-12 EP disclosed
US-4871780-A VINYL HALIDES AND ACRYLATED POLYCAPROLACTONE COPOLYMERIZED THE B.F. GOODRICH COMPANY (US) 1989-10-03 US disclosed
US-4871801-A ANHYDRIDE-FUNCTIONALIZED COPOLYMER OF VINYL HALIDE AND ETHYLENICALLY UNSATURATED HYDROXY-CONTAINING MONOMER, REACTED WITH SECOND COREACTIVE MOIETY THE B. F. GOODRICH COMPANY (US) 1989-10-03 US disclosed
EP-0177956-B1 LOW MOLECULAR WEIGHT VINYL HALIDE/VINYL ESTER COPOLYMERS BY AQUEOUS POLYMERIZATION The B.F. GOODRICH Company (US) 1989-04-19 EP disclosed
US-4797458-A MOLDING MATERIALS THE B.F. GOODRICH COMPANY (US) 1989-01-10 US disclosed
CN-87106075-A Use the colloid-stabilised ethylene halide polyreaction of amine-thiol chain transfer agents 1988-06-29 CN disclosed
EP-0258832-A2 Colloidal stable vinyl halide polymerizations with mercaptan chain transfer agents THE B.F. GOODRICH COMPANY (US) 1988-03-09 EP disclosed
EP-0243820-A2 Low molecular weight copolymers of vinyl halide/vinyl acetate produced by aqueous polymerization The B.F. GOODRICH Company (US) 1987-11-04 EP disclosed
CN-85107445-A Make the multipolymer of lower molecular weight halogen ethylene/vinyl ester by the water polyreaction 1986-09-03 CN disclosed
EP-0177956-A2 Low molecular weight vinyl halide/vinyl ester copolymers by aqueous polymerization The B.F. GOODRICH Company (US) 1986-04-16 EP disclosed
EP-0030439-A2 Polymerisation process for preparation of non-aqueous dispersions of microparticles and coating compositions containing said microparticles IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1981-06-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10758478-B2 Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same CHERP, ORAI1, CA2 FFAR3 3335/4885CA1 67/4885CA2 3/4885
US-20090326246-A1 Method for Production of Optically Active 3-Amino-Nitrogenated Compound PNMT, NPEPPS, GNMT FFAR3 534/4885CA1 3988/4885CA2 2917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.